Status:
UNKNOWN
Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Carcinoma, Non-Small Cell Lung
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the safety and efficacy of the concurrent use of erlotinib and radiation therapy in the treatment of locally advanced non-small lung cancer.
Detailed Description
Non-small cell lung cancer (NSCLC) is still the leading cause of cancer death world-wide. Radiation therapy (RT) is one of the most important treatment choices in locally advanced NSCLC. Combination o...
Eligibility Criteria
Inclusion
- Aged 18-70 years，
- Patients with stage IIIA-IIIB NSCLC
- adequate hematologic (WBC and platelet counts within normal limits), hepatic (total bilirubin level \<= two times the upper limit of normal), and renal (creatinine clearance \>= 50mL/min) functions
- No history of chemotherapy or less than 4 cycles neoadjuvant chemotherapy
- Can not tolerate or refuse concurrent chemoradiotherapy
- No history of thoracic RT
- Written informed consent obtained
Exclusion
- With other malignancy
- With severe cardiopulmonary disease
- Compromised liver or renal function that could not tolerate the combined therapy
- Received thoracic RT before
- Pregnant or breast-feeding women
- Present with active infection
- Uncontrolled diabetes
- Concurrent use of other anti-cancer agents
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00973310
Start Date
October 1 2009
End Date
December 1 2016
Last Update
December 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy
Tianjin, Tianjin Municipality, China, 300060